Pharma Reviews: Cipla will maintain its EBITDA at 22% in FY22, says Kedar Upadhye

"To put a brake on the way the number of COVID cases is surging in India, it is our and pharma industry's responsibility to launch all the drugs in India ...
Read more: Cipla will maintain its EBITDA at 22% in FY22, says Kedar Upadhye